Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT07576010
PHASE1

Steroids Combined With Ruxolitinib as First-Line Therapy for Grade II Acute Graft-versus-Host Disease

Sponsor: Daihong Liu

View on ClinicalTrials.gov

Summary

This study aims to evaluate the efficacy and safety of low-dose corticosteroids combined with ruxolitinib in the treatment of grade II acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation.

Official title: An Exploratory Clinical Study of Low-Dose Steroids Combined With Ruxolitinib as First-Line Therapy for Grade II Acute Graft-versus-Host Disease

Key Details

Gender

All

Age Range

Any - 75 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2025-01-17

Completion Date

2027-12-30

Last Updated

2026-05-08

Healthy Volunteers

No

Interventions

DRUG

steroids 、ruxolitinib

Patients with acute grade II GVHD are treated with a combination of methylprednisolone (0.5 mg/kg/day) and ruxolitinib.

Locations (1)

Chinese PLA General Hospital

Beijing, Beijing Municipality, China